Missing the Target #5: Improving AIDS Drug Access ... - CD8 T cells

UGANDAExtracts from the MoH’s report on the supervision of ARV supply chain management(third quarter of 2007)DistrictSironkoButalejaKapchorwaNakapiripiritKumiAbimName offacilityBudadiriHC IVMayembeHC IVBusolweHospitalKapchorwaHospitalTokora HCIVAtutur HCIVAbimHospitalNumber ofpatients oncotrimoxazoleprophylaxisNumberof patientson firstlineARTMaximumcapacitythat can behandled atcenterDays outof stockin last sixmonths148 66 0–99 60 days1,650 32 100–199 30 days516 103 100–199 0298 51 100–199 15 days91 15 0–99 45 days1,434 408 300–399 0131 43 0–99 30 daysSource: Uganda MoHThe underlying cause of drug stock-outs has a lot to do with demand outstrippingsupply. As noted previously, the number of people currently on ART was less thanhalf of those estimated to be in need. The situation has been made worse by aninefficient procurement and distribution system, which on occasions has resultedin the expiry of ARVs in the national stores as well as at district levels. This hasoccurred even as ART centers reported stock-outs, and resulted in acknowledgementof the need to monitor third party–supplied ARVs.The stock-out problem has reached such critical levels that the National Forumof People Living with HIV/AIDS Networks in Uganda (NAFOPHANU) and theConsortium of Advocates for Access to Treatment (CAAT) led a public demonstrationand presented a petition to the MoH in August 2007, pleading for consistent andimproved supply of ARVs to all the accredited 212 ART centers across the country.1 Annual Health Sector Performance Report 2006/2007, October 200799